Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer

1.

Rogers HW, M a W, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;6360(10):1081–6. https://doi.org/10.1001/jamadermatol.2015.1187.CrossRef

2.

Zalaudek I, Argenziano G, Soyer HP, Corona R, Sera F, Blum A, et al. Three-point checklist of dermoscopy: an open internet study. Br J Dermatol. 2006;154(3):431–7. https://doi.org/10.1111/j.1365-2133.2005.06983.x.PubMedCrossRef

3.

Russo T, Piccolo V, Lallas A, Jacomel J, Moscarella E, Alfano R, et al. Dermoscopy of malignant skin tumours: what’s new? Dermatology. 2017;233(1):64–73. https://doi.org/10.1159/000472253. PubMedCrossRef

4.

Kreusch JF. Vascular patterns in skin tumors. Clin Dermatol. 2002;20(3):248–54. https://doi.org/10.1016/S0738-081X(02)00227-4.

5.

Ulrich M, Von Braunmuehl T, Kurzen H, Dirschka T, Kellner C, Sattler E, et al. The sensitivity and specificity of optical coherence tomography for the assisted diagnosis of nonpigmented basal cell carcinoma: an observational study. Br J Dermatol. 2015;173(2):428–35. https://doi.org/10.1111/bjd.13853.PubMedCrossRef

6.

Markowitz O, Schwartz M, Feldman E, et al. Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stag ... Page 1 sur 7 Evaluation of Optical Coherence Tomography as a Means of Identifying Earlier Stage Basal Cell Carcinomas while Reducing the Use of Diagnostic Biopsy. J Clin Aesthet Dermatol. 2015;8:14–20.PubMedPubMedCentral

7.

Olsen J, Themstrup L, De Carvalho N, Mogensen M, Pellacani G, Jemec GBE. Diagnostic accuracy of optical coherence tomography in actinic keratosis and basal cell carcinoma. Photodiagn Photodyn Ther. 2016;16:44–9. https://doi.org/10.1016/j.pdpdt.2016.08.004.CrossRef

8.

Mogensen M, Joergensen TM, Nürnberg BM, Morsy HA, Thomsen JB, Thrane L, et al. Assessment of optical coherence tomography imaging in the diagnosis of non-melanoma skin cancer and benign lesions versus normal skin: observer-blinded evaluation by dermatologists and pathologists. Dermatol Surg. 2009;35(6):965–72. https://doi.org/10.1111/j.1524-4725.2009.01164.x.PubMedCrossRef

9.

Gambichler T, Schmid-Wendtner MH, Plura I, Kampilafkos P, Stücker M, Berking C, et al. A multicentre pilot study investigating high-definition optical coherence tomography in the differentiation of cutaneous melanoma and melanocytic naevi. J Eur Acad Dermatol Venereol. 2015;29(3):537–41. https://doi.org/10.1111/jdv.12621.PubMedCrossRef

10.

Boone MALM, Suppa M, Dhaenens F, Miyamoto M, Marneffe A, Jemec GBE, et al. In vivo assessment of optical properties of melanocytic skin lesions and differentiation of melanoma from non-malignant lesions by high-definition optical coherence tomography. Arch Dermatol Res. 2016;308(1):7–20. https://doi.org/10.1007/s00403-015-1608-5.PubMedCrossRef

11.

Marneffe A, Suppa M, Miyamoto M, Del Marmol V, Boone M. Validation of a diagnostic algorithm for the discrimination of actinic keratosis from normal skin and squamous cell carcinoma by means of high-definition optical coherence tomography. Exp Dermatol. 2016;25(9):684–7. https://doi.org/10.1111/exd.13036.PubMedCrossRef

12.

Li G. High-definition optical coherence tomography in the diagnosis of basal cell carcinoma evaluated by an experienced versus inexperienced investigator. J Clin Exp Dermatol Res. 2014;5(4) https://doi.org/10.4172/2155-9554.1000227.

13.

Levine A, Markowitz O. vivo reflectance confocal microscopy. Cutis. 2017;99(6):399–402.PubMed

14•.

Rajadhyaksha M, Marghoob A, Rossi A, Halpern AC, Nehal KS. Reflectance confocal microscopy of skin in vivo: from bench to bedside. Lasers Surg Med. 2017;49(1):7–19. https://doi.org/10.1002/lsm.22600. This paper reviews and higlights advances in reflectance confocal microscopy imaging. PubMedCrossRef

15.

Ulrich M, Krueger-Corcoran D, Roewert-Huber J, Sterry W, Stockfleth E, Astner S. Reflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratoses. Dermatology. 2010;220(1):15–24. https://doi.org/10.1159/000254893.PubMedCrossRef

16.

Astner S, Swindells K, González S, Stockfleth E, Lademann J. Confocal microscopy: innovative diagnostic tools for monitoring of noninvasive therapy in cutaneous malignancies. Drug Discov Today Dis Mech. 2008;5(1):81–91. https://doi.org/10.1016/j.ddmec.2008.04.002.CrossRef

17.

Malvehy J, Alarcon I, Montoya J, Rodríguez-Azeredo R, Puig S. Treatment monitoring of 0.5% 5-fluorouracil and 10% salicylic acid in clinical and subclinical actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy. J Eur Acad Dermatol Venereol. 2016;30(2):258–65. https://doi.org/10.1111/jdv.13445.PubMedCrossRef

18.

Lanoue J, Goldenberg G. Basal cell carcinoma—a comprehensive review of existing and emerging nonsurgical therapies. J Clin Aesthetic Dermatol. 2016;9:26–36.

19.

Galiczynski EM, Vidimos AT. Nonsurgical treatment of nonmelanoma skin cancer. Dermatol Clin. 2011;29(2):297–309. https://doi.org/10.1016/j.det.2011.01.011.PubMedCrossRef

20.

Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol. 2009;145(12):1431–8. https://doi.org/10.1001/archdermatol.2009.291.PubMedCrossRef

21.

Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol. 2013;31(6):792–8. https://doi.org/10.1016/j.clindermatol.2013.08.020.PubMedCrossRef

22.

Alter M, Hillen U, Leiter U, Sachse M, Gutzmer R. Current diagnosis and treatment of basal cell carcinoma. JDDG J Der Dtsch Dermatologischen Gesellschaft. 2015;13(9):863–75. https://doi.org/10.1111/ddg.12798.

23.

Micali G, Lacarrubba F, Nasca MR, de Pasquale R, Micali G, Lacarrubba F, et al. The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin’s syndrome. Clin Exp Dermatol. 2003;28(s1):19–23. https://doi.org/10.1046/j.1365-2230.28.s1.7.x. PubMedCrossRef

24.

Roseeuw D. The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. Clin Exp Dermatol. 2003;28(Suppl 1):30–2. https://doi.org/10.1046/j.1365-2230.28.s1.10.x.PubMedCrossRef

25.

Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol. 2004;50(5):722–33. https://doi.org/10.1016/j.jaad.2003.11.066.PubMedCrossRef

26.

FJ B-H, Perkins W, Bong J, HC W. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007:N.PAG-N.PAG 1p. doi:https://doi.org/10.1002/14651858.CD003412.pub2.www.cochranelibrary.com.

27.

Quirk C, Gebauer K, De’Ambrosis B, Slade HB, Meng TC. Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. Cutis. 2010;85(6):318–24.PubMed

28.

Gollnick H, Barona CG, Frank RG, Ruzicka T, Megahed M, Maus J, et al. Recurrence rate of superficial basal cell carcinoma following treatment with imiquimod 5% cream: conclusion of a 5-year long-term follow-up study in Europe. Eur J Dermatol. 2008;18(6):677–82. https://doi.org/10.1684/ejd.2008.0519. PubMed

29.

McKay KM, Sambrano BL, Fox PS, Bassett RL, Chon S, Prieto VG. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC. Br J Dermatol. 2013;169(3):549–54. https://doi.org/10.1111/bjd.12402.PubMedCrossRef

30•.

Williams HC, Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol. 2017;137(3):614–9. https://doi.org/10.1016/j.jid.2016.10.019. This research reports 5-year benefit for topical imiquimod compared with surgery for superficial or nodular basal cell carcinoma. PubMedCrossRef

31.

Bath-Hextall F, Ozolins M, Armstrong SJ, Colver GB, Perkins W, Miller PSJ, et al. Surgical excision versus imiquimod 5% cream for nodular and superficial basal-cell carcinoma (SINS): a multicentre, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(1):96–105. https://doi.org/10.1016/S1470-2045(13)70530-8.PubMedCrossRef

32.

Hadley G, Derry S, R a M. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol. 2006;126(6):1251–5. https://doi.org/10.1038/sj.jid.5700264.PubMedCrossRef

33.

Swanson N, Smith CC, Kaur M, Goldenberg G. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: two phase 3, multicenter, randomized, double-blind, placebo-controlled studies. J Drugs Dermatol. 2014;13(2):166–9.PubMed

34.

Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54(6):1025–32. https://doi.org/10.1016/j.jaad.2006.01.055.PubMedCrossRef

35.

Mackenzie-Wood a KS, de Launey J, Wilkinson B, Owens ML. Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol. 2001;44(3):462–70. https://doi.org/10.1067/mjd.2001.111335.PubMedCrossRef

36.

Goh MSY. Invasive squamous cell carcinoma after treatment of carcinoma in situ with 5% imiquimod cream. Australas J Dermatol. 2006;47(3):186–8. https://doi.org/10.1111/j.1440-0960.2006.00269.x. PubMedCrossRef

37.

Apalla Z, Lallas A, Tzellos T, Sidiropoulos T, Lefaki I, Trakatelli M, et al. Applicability of dermoscopy for evaluation of patients’ response to nonablative therapies for the treatment of superficial basal cell carcinoma. Br J Dermatol. 2014;170(4):809–15. https://doi.org/10.1111/bjd.12749.PubMedCrossRef

38.

Husein-ElAhmed H, Fernandez-Pugnaire MA. Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod. An Bras Dermatol. 2016;91(6):764–9. https://doi.org/10.1590/abd1806-4841.20165255.PubMedPubMedCentralCrossRef

39.

Banzhaf CA, Themstrup L, Ring HC, Mogensen M, Jemec GBE. Optical coherence tomography imaging of non-melanoma skin cancer undergoing imiquimod therapy. Skin Res Technol. 2014;20(2):170–6. https://doi.org/10.1111/srt.12102.PubMedCrossRef

40.

Gross K, Kircik L, Kricorian G. 5% 5-fluorouracil cream for the treatment of small superficial basal cell carcinoma: efficacy, tolerability, cosmetic outcome, and patient satisfaction. Dermatologic Surg. 2007;33(4):433–9. https://doi.org/10.1111/j.1524-4725.2007.33090.x.

41.

Romagosa R, Saap L, Givens M, Salvarrey A, He JL, Hsia SL, et al. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier. Dermatol Surg. 2000;26(4):338–40. https://doi.org/10.1046/j.1524-4725.2000.99227.x.PubMedCrossRef

42.

Reymann F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment. A 10-year follow-up study. Dermatologica. 1979;158(5):368–72. https://doi.org/10.1159/000250782.PubMedCrossRef

43.

Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol. 2007;157(157 Suppl):34–40. https://doi.org/10.1111/j.1365-2133.2007.08271.x.PubMedCrossRef

44.

Barrera MV, Herrera E. Topical chemotherapy for actinic keratosis and nonmelanoma skin cancer: current options and future perspectives. Actas Dermosifiliogr. 2007;98(8):556–62. https://doi.org/10.1016/S0001-7310(07)70133-3.PubMedCrossRef

45.

Weiss J, Menter A, Hevia O, Jones T, Ling M, Rist T, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis. 2002;70(2 Suppl):22–9.PubMed

46.

Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther. 2002;24(6):990–1000. https://doi.org/10.1016/S0149-2918(02)80012-1.PubMedCrossRef

47.

Levy S, Furst K, Chern W. A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis. Clin Ther. 2001;23(6):908–20. https://doi.org/10.1016/S0149-2918(01)80078-3.PubMedCrossRef

48.

Jorizzo JL, Carney PS, Ko WT, Robins P, Weinkle SH, Werschler WP. Fluorouracil 5% and 0.5% creams for the treatment of actinic keratosis: equivalent efficacy with a lower concentration and more convenient dosing schedule. Cutis. 2004;74(6 Suppl):18–23.PubMed

49.

Askew DA, Mickan SM, Soyer HP, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis—a systematic review of randomized controlled trials. Int J Dermatol. 2009;48(5):453–63. https://doi.org/10.1111/j.1365-4632.2009.04045.x.PubMedCrossRef

50.

Simon JC, Dominicus R, Karl L, Rodríguez R, Willers C, Dirschka T. A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis. J Eur Acad Dermatol Venereol. 2015;29(5):881–9. https://doi.org/10.1111/jdv.12702.PubMedCrossRef

51.

Morton C, Horn M, Leman J, Tack B, Bedane C, Tjioe M, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol. 2006;142(6):729–35. https://doi.org/10.1001/archderm.142.6.729.PubMedCrossRef

52.

Ulrich M, Reinhold U, Falqués M, Rodriguez Azeredo R, Stockfleth E. Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5% /salicylic acid 10% in the field-directed treatment of sub-clinical lesions of actinic keratosis: sub-analysis of a phase III, randomised, double-blind, vehicle-controlled trial. J Eur Acad Dermatol Venereol. 2017; https://doi.org/10.1111/jdv.14611.

53.

Ishioka P, Maia M, Rodrigues SB, Marta AC, Hirata SH. Evaluation of the therapeutic results of actinic keratosis treated with topical 5% fluorouracil by reflectance confocal laser microscopy: preliminary study. An Bras Dermatol. 2015;90(3):426–9. https://doi.org/10.1590/abd1806-4841.20153437.PubMedPubMedCentralCrossRef

54.

Goldenberg G, Perl M. Actinic keratosis: update on field therapy. J Clin Aesthet Dermatol. 2014;7(10):28–31.PubMedPubMedCentral

55.

Clark CM, Furniss M, Mackay-Wiggan JM. Basal cell carcinoma: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):197–216. https://doi.org/10.1007/s40257-014-0070-z.PubMedCrossRef

56.

Lebwohl M, Swanson N, Anderson LL, Melgaard A, Xu Z, Berman B. Ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–9. https://doi.org/10.1056/NEJMoa1111170.PubMedCrossRef

57.

Lebwohl M, Shumack S, Gold LS, Melgaard A, Larsson T, Tyring SK. Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–70. https://doi.org/10.1001/jamadermatol.2013.2766.PubMedCrossRef

58.

Siller G, Rosen R, Freeman M, Welburn P, Katsamas J, Ogbourne SM. PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial. Australas J Dermatol. 2010;51(2):99–105. https://doi.org/10.1111/j.1440-0960.2010.00626.x.PubMedCrossRef

59.

Maier T, Cekovic D, Ruzicka T, Sattler EC, Berking C. Treatment monitoring of topical ingenol mebutate in actinic keratoses with the combination of optical coherence tomography and reflectance confocal microscopy: a case series. Br J Dermatol. 2015;172(3):816–8. https://doi.org/10.1111/bjd.13304.PubMedCrossRef

60.

Ulrich M, Lange-Asschenfeldt S, Skak K, Skov T, Osterdal M, Rowert-Huber H, et al. Biological effects of ingenol mebutate gel in moderate to severe actinic fields assessed by reflectance confocal microscopy: a phase I study. J Drugs Dermatol. 2016;15(10):1181–9.PubMed

61.

Markowitz O, Schwartz M, Feldman E, Bieber AMY, Bienenfeld A, Nandanan N, et al. Defining field cancerization of the skin using noninvasive optical coherence tomography imaging to detect and monitor actinic. J Clin Aesthet Dermatol. 2016;9:18–26.PubMedPubMedCentral

62.

Williams V, Rosen T, Ceilley RI, del Rosso JQ, Stockfleth E. Topical treatment of skin cancer. Second Edi Elsevier Inc; 2011. https://doi.org/10.1016/B978-1-4377-1788-4.00043-5.

63.

Cohen DK, Lee PK. Photodynamic therapy for non-melanoma skin cancers. Cancers (Basel) 2016;8(10). https://doi.org/10.3390/cancers8100090.

64.

Savoia P, Deboli T, Previgliano A, Broganelli P. Usefulness of photodynamic therapy as a possible therapeutic alternative in the treatment of basal cell carcinoma. Int J Mol Sci. 2015;16(10):23300–17. https://doi.org/10.3390/ijms161023300.PubMedPubMedCentralCrossRef

65.

Tarstedt M, Gillstedt M, Wennberg Larkö A-M, Paoli J. Aminolevulinic acid and methyl aminolevulinate equally effective in topical photodynamic therapy for non-melanoma skin cancers. J Eur Acad Dermatol Venereol. 2016;30(3):420–3. https://doi.org/10.1111/jdv.13558.PubMedCrossRef

66.

Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(5):536–44. https://doi.org/10.1111/jdv.12031.PubMedCrossRef

67.

Piacquadio DJ, Chen DM, Farber HF, Fowler JF, Glazer SD, Goodman JJ, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp. Arch Dermatol. 2004;140(1):41–6. https://doi.org/10.1001/archderm.140.1.41.PubMedCrossRef

68.

Griffin LL, Lear JT. Photodynamic therapy and non-melanoma skin cancer. Cancers (Basel) 2016;8(10). https://doi.org/10.3390/cancers8100098.

69.

Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, et al. A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BF-Rho. Br J Dermatol. 2016;175(4):696–705. https://doi.org/10.1111/bjd.14498. PubMedCrossRef

70.

Gupta AK, Paquet M, Villanueva E, Brintnell W. Interventions for actinic keratoses. Cochrane Database Syst Rev. 2012;12:CD004415. https://doi.org/10.1002/14651858.CD004415.pub2. PubMed

71.

Patel G, Armstrong AW, Eisen DB. Efficacy of photodynamic therapy vs other interventions in randomized clinical trials for the treatment of actinic keratoses: a systematic review and meta-analysis. JAMA Dermatol. 2014;150(12):1281–8. https://doi.org/10.1001/jamadermatol.2014.1253.PubMedCrossRef

72.

Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact application of 5-aminolevulinate. J Biomed Opt. 2015;15:51607. https://doi.org/10.1117/1.3484255. CrossRef

73.

Pariser DM, Houlihan A, Ferdon MB, Berg JE. PDT-AK investigational group. Randomized vehicle-controlled study of short drug incubation aminolevulinic acid photodynamic therapy for actinic keratoses of the face or scalp. Dermatol Surg. 2016;42(3):296–304. https://doi.org/10.1097/DSS.0000000000000630. PubMedPubMedCentralCrossRef

74.

Tschen EH, Wong DS, Pariser DM, Dunlap FE, Houlihan A, Ferdon MB, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre clinical trial with 12-month follow up. Br J Dermatol. 2006;155(6):1262–9. https://doi.org/10.1111/j.1365-2133.2006.07520.x.PubMedCrossRef

75.

Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix®)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol. 2005;85(5):424–8. https://doi.org/10.1080/00015550510032887.PubMedCrossRef

76.

Roozeboom MH, Arits AH, Nelemans PJ, Kelleners-Smeets NW. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials. Br J Dermatol. 2012;167(4):733–56. https://doi.org/10.1111/j.1365-2133.2012.11061.x.PubMedCrossRef

77.

Mosterd K, Thissen MRTM, Nelemans P, Kelleners-Smeets NWJ, Janssen RLLT, Broekhof KGME, et al. Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. Br J Dermatol. 2008;159(4):864–70. https://doi.org/10.1111/j.1365-2133.2008.08787.x.PubMedCrossRef

78.

Fantini F, Greco a DGC, Cesinaro a M, Venturini M, Zane C, et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25(8):896–901. https://doi.org/10.1111/j.1468-3083.2010.03877.x.PubMedCrossRef

79.

Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647–54. https://doi.org/10.1016/S1470-2045(13)70143-8.PubMedCrossRef

80.

Cosgarea R, Susan M, Crisan M, Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(8):980–4. https://doi.org/10.1111/j.1468-3083.2012.04619.x.PubMedCrossRef

81.

Szeimies RM, Ibbotson S, Murrell DF, Rubel D, Frambach Y, De Berker D, et al. A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. J Eur Acad Dermatol Venereol. 2008;22(11):1302–11. https://doi.org/10.1111/j.1468-3083.2008.02803.x.PubMedCrossRef

82.

Rhodes LE, De Rie M, Enstrom Y, Groves R, Morken T, Goulden V, et al. Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Arch Dermatol. 2007;143(9):1131–6. https://doi.org/10.1001/archderm.143.9.1131.ABSTRACT. PubMedCrossRef

83.

De Vijlder HC, Sterenborg HJCM, Martino Neumann HA, Robinson DJ, De Haas ERM. Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta Derm Venereol. 2012;92(6):641–7. https://doi.org/10.2340/00015555-1448.PubMedCrossRef

84.

Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol. 2003;148(3):539–43. https://doi.org/10.1046/j.1365-2133.2003.05033.x.PubMedCrossRef

85.

Christensen E, Mørk C, Skogvoll E. High and sustained efficacy after two sessions of topical 5-aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10-year follow-up study. Br J Dermatol. 2012;166(6):1342–8. https://doi.org/10.1111/j.1365-2133.2012.10878.x.PubMedCrossRef

86.

Themstrup L, Banzhaf CA, Mogensen M, Jemec GBE. Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions. Photodiagn Photodyn Ther. 2014;11(1):7–12. https://doi.org/10.1016/j.pdpdt.2013.11.003.CrossRef

87.

Longo C, Casari A, Pepe P, Moscarella E, Zalaudek I, Argenziano G, et al. Confocal microscopy insights into the treatment and cellular immune response of basal cell carcinoma to photodynamic therapy. Dermatology. 2012;225(3):264–70. https://doi.org/10.1159/000345106.PubMedCrossRef

88.

Venturini M, Sala R, Gonzàlez S, Calzavara-Pinton PG. Reflectance confocal microscopy allows in vivo real-time noninvasive assessment of the outcome of methyl aminolaevulinate photodynamic therapy of basal cell carcinoma. Br J Dermatol. 2013;168(1):99–105. https://doi.org/10.1111/bjd.12052.PubMedCrossRef

89.

Segura S, Puig S, Carrera C, Lecha M, Borges V, Malvehy J. Non-invasive management of non-melanoma skin cancer in patients with cancer predisposition genodermatosis: a role for confocal microscopy and photodynamic therapy. J Eur Acad Dermatol Venereol. 2011;25(7):819–27. https://doi.org/10.1111/j.1468-3083.2010.03871.x.PubMedCrossRef

90.

Konnikov N, Avram M, Jarell A, Tannous Z. Pulsed dye laser as a novel non-surgical treatment for basal cell carcinomas: response and follow up 12-21 months after treatment. Lasers Surg Med. 2011;43(2):72–8. https://doi.org/10.1002/lsm.21035.PubMedCrossRef

91.

Minars N, Blyumin-Karasik M. Treatment of basal cell carcinomas with pulsed dye laser: a case series. J Skin Cancer. 2012;2012:286480. https://doi.org/10.1155/2012/286480.PubMedPubMedCentralCrossRef

92.

Shah SM, Konnikov N, Duncan LM, Tannous ZS. The effect of 595 nm pulsed dye laser on superficial and nodular basal cell carcinomas. Lasers Surg Med. 2009;41(6):417–22. https://doi.org/10.1002/lsm.20787.PubMedCrossRef

93.

Tran HT, Lee RA, Oganesyan G, Jiang SB. Single treatment of non-melanoma skin cancers using a pulsed-dye laser with stacked pulses. Lasers Surg Med. 2012;44(6):459–67. https://doi.org/10.1002/lsm.22032.PubMedCrossRef

94.

Karsai S, Friedl H, Buhck H, Jünger M, Podda M. The role of the 595-nm pulsed dye laser in treating superficial basal cell carcinoma: outcome of a double-blind randomized placebo-controlled trial. Br J Dermatol. 2015;172(3):677–83. https://doi.org/10.1111/bjd.13266.PubMedCrossRef

95.

Soleymani T, Abrouk M, Kelly KM. An analysis of laser therapy for the treatment of nonmelanoma skin cancer. Dermatol Surg. 2017;43(5):615–24. https://doi.org/10.1097/DSS.0000000000001048.PubMedPubMedCentralCrossRef

96.

Ortiz AE, Anderson RR, Avram MM. 1064 nm long-pulsed Nd:YAG laser treatment of basal cell carcinoma. Lasers Surg Med. 2015;47(2):106–10. https://doi.org/10.1002/lsm.22310.PubMedCrossRef

97.

Kavoussi H, Ebrahimi A, Rezaei M. Treatment and cosmetic outcome of superpulsed C02 laser for basal cell carcinoma. Acta Dermatovenerol Alpina Pannonica Adriat. 2013;22:57–61. https://doi.org/10.2478/v10162-012-0035-y.

98.

Weiss ET, Brauer JA, Anolik R, Reddy KK, Karen JK, Hale EK, et al. 1927-nm Fractional resurfacing of facial actinic keratoses: a promising new therapeutic option. J Am Acad Dermatol. 2013;68(1):98–102. https://doi.org/10.1016/j.jaad.2012.05.033.PubMedCrossRef

99.

Hibler BP, Sierra H, Cordova M, Phillips W, Rajadhyaksha M, Nehal KS, et al. Carbon dioxide laser ablation of basal cell carcinoma with visual guidance by reflectance confocal microscopy: a proof-of-principle pilot study. Br J Dermatol. 2016;174(6):1359–64. https://doi.org/10.1111/bjd.14414.PubMedPubMedCentralCrossRef

100.

Sierra H, Damanpour S, Hibler B, Nehal K, Rossi A, Rajadhyaksha M. Confocal imaging of carbon dioxide laser-ablated basal cell carcinomas: an ex-vivo study on the uptake of contrast agent and ablation parameters. Lasers Surg Med. 2016;48(2):133–9. https://doi.org/10.1002/lsm.22415.PubMedCrossRef

101.

Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366(23):2171–9. https://doi.org/10.1056/NEJMoa1113713.PubMedPubMedCentralCrossRef

102.

Maier T, Kulichova D, Ruzicka T, Berking C. Noninvasive monitoring of basal cell carcinomas treated with systemic hedgehog inhibitors: pseudocysts as a sign of tumor regression. J Am Acad Dermatol. 2014;71(4):725–30. https://doi.org/10.1016/j.jaad.2014.04.007.PubMedCrossRef

103.

Peris K, Licitra L, Ascierto PA, Corvò R, Simonacci M, Picciotto F, et al. Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus. Future Oncol. 2015;11(4):703–12. https://doi.org/10.2217/fon.14.281.PubMedCrossRef

104•.

Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17(1):332. https://doi.org/10.1186/s12885-017-3286-5. This research article reports long-term safety and final investigator-assessed efficacy results in patients with metastatic or locally advanced basal cell carcinoma treated with vismodegib. PubMedPubMedCentralCrossRef

105.

Ibrahim O, Gastman B, Zhang A. Advances in diagnosis and treatment of nonmelanoma skin cancer. Ann Plast Surg. 2014;73(5):615–9. https://doi.org/10.1097/SAP.0000000000000330.PubMedCrossRef

106.

Burness CB, Scott LJ. Sonidegib: a review in locally advanced basal cell carcinoma. Target Oncol. 2016;11(2):239–46. https://doi.org/10.1007/s11523-016-0418-9.PubMedCrossRef

107.

Basset-Seguin N, Hauschild A, Grob JJ, Kunstfeld R, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015;16(6):729–36. https://doi.org/10.1016/S1470-2045(15)70198-1.PubMedCrossRef

108.

Migden MR, Guminski A, Gutzmer R, Dirix L, Lewis KD, Combemale P, et al. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015;16(6):716–28. https://doi.org/10.1016/S1470-2045(15)70100-2.PubMedCrossRef

109•.

Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venereol. 2017;38:42–9. https://doi.org/10.1111/jdv.14542. This research article reports long-term safety and efficacy of sonidegib in locally advanced and metastatic basal cell carcinoma at 18- and 30- month analyses.

110.

Ally MS, Aasi S, Wysong A, Teng C, Anderson E, Bailey-Healy I, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol. 2014;71(5):904–911.e1. https://doi.org/10.1016/j.jaad.2014.05.020.PubMedCrossRef

111.

Tang JY, Ally MS, Chanana AM, Mackay-Wiggan JM, Aszterbaum M, Lindgren JA, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17(12):1720–31. https://doi.org/10.1016/S1470-2045(16)30566-6.PubMedCrossRef

112.

Lear JT, Corner C, Dziewulski P, Fife K, Ross GL, Varma S, et al. Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective. Br J Cancer. 2014;111(8):1476–81. https://doi.org/10.1038/bjc.2014.270.PubMedPubMedCentralCrossRef

113.

Lacouture ME, Dreno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, et al. Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist. 2016;21(10):1218–29. https://doi.org/10.1634/theoncologist.2016-0186.PubMedPubMedCentralCrossRef

114.

Markowitz O, Schwartz M. The use of noninvasive optical coherence tomography to monitor the treatment progress of vismodegib and imiquimod 5% cream in a transplant patient with advanced basal cell carcinoma of the nose. J Clin Aesthet Dermatol. 2016;9(8):37–41.PubMedPubMedCentral

115.

Kim J, Tang JY, Gong R, Kim J, Lee JJ, Clemons KV, et al. Itraconazole, a commonly used antifungal that inhibits hedgehog pathway activity and cancer growth. Cancer Cell. 2010;17(4):388–99. https://doi.org/10.1016/j.ccr.2010.02.027.PubMedPubMedCentralCrossRef

116.

Kim DJ, Kim J, Spaunhurst K, Montoya J, Khodosh R, Chandra K, et al. Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol. 2014;32(8):745–51. https://doi.org/10.1200/JCO.2013.49.9525.PubMedCrossRef

117.

Parikh S, Patel V, Ratner D. Advances in the management of cutaneous squamous cell carcinoma. F1000Prime Rep. 2014;6:1–8. https://doi.org/10.12703/P6-70.CrossRef

118.

Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26. https://doi.org/10.1200/JCO.2010.34.1735.PubMedCrossRef

119.

McGregor S, Minni J. Superficial radiation therapy for the treatment of nonmelanoma skin cancers. Am Heart J. 1973;85:563–8.CrossRef

120.

Cho M, Gordon L, Rembielak A, Woo TCS. Utility of radiotherapy for treatment of basal cell carcinoma: a review. Br J Dermatol. 2014;171(5):968–73. https://doi.org/10.1111/bjd.13253.PubMedCrossRef

121.

Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67(6):1235–41. https://doi.org/10.1016/j.jaad.2012.06.001.PubMedCrossRef

122.

Cooper JS. Radiation therapy in the treatment of skin cancers. Second Edi. Elsevier Inc.; 2011. https://doi.org/10.1016/B978-1-4377-1788-4.00052-6.

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Update on Noninvasive Diagnostic Imaging and Management of Nonmelanoma Skin Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2018

Review Update on Topical Therapy for Psoriasis

Enteropathy in Psoriasis: A Systematic Review of Gastrointestinal Disease Epidemiology and Subclinical Inflammatory and Functional Gut Alterations

A Review and Update of Phototherapy Treatment Options for Psoriasis

Update on Oral Therapy for Psoriasis

Evaluation of the Itchy Patient

Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis